<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.109326</article-id><article-id pub-id-type="publisher-id">ACM-37832</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20200900000_91489854.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  免疫性血小板减少症相关性疲劳
  Immune Thrombocytopenia-Related Fatigue
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>吴</surname><given-names>晓勇</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>云龙</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>贵州中医药大学第一附属医院，贵州 贵阳</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>08</day><month>09</month><year>2020</year></pub-date><volume>10</volume><issue>09</issue><fpage>2162</fpage><lpage>2168</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    疲劳是与健康相关生活质量(HRQoL)的重要方面，也是慢性病常见的表现，严重影响患者生活质量的同时，可能导致严重的社会经济后果。成人和儿童免疫性血小板减少症(Immune thrombocytopenia, ITP)患者中大部分存在疲劳，经验证的、可靠的疲劳量表已用于ITP评估，这有助于对其发病机制和干预效果进行调查研究。有效的ITP治疗可以改善疲劳，但临床医生在评估ITP疾病负担时应考虑干预疲劳的策略，可借鉴和参考其他慢性病相关性疲劳的治疗方法和策略，ITP相关疲劳也可从中医药治疗中获益。
    Fatigue is an important aspect of health-related quality of life (HRQoL). It is also a common manifestation of chronic diseases, which seriously affects the quality of life of patients and can have significant socioeconomic consequences. Most of both adults and children with immune thrombocytopenia (ITP) suffer from fatigue. Validated, reliable fatigue scale has been developed for the use in ITP. These will facilitate future investigation of its pathogenesis and the effectiveness of intervention. Although effective ITP treatment can improve fatigue, clinicians should consider strategies for intervention fatigue when assessing the burden of ITP disease. Clinicians can learn from other chronic disease related fatigue treatment methods and strategies, ITP related fatigue can also benefit from the treatment of Traditional Chinese Medicine. 
  
 
</p></abstract><kwd-group><kwd>免疫性血小板减少症，疲劳，生活质量, Immune Thrombocytopenia</kwd><kwd> Fatigue</kwd><kwd> Quality of Life</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>疲劳是与健康相关生活质量(HRQoL)的重要方面，也是慢性病常见的表现，严重影响患者生活质量的同时，可能导致严重的社会经济后果。成人和儿童免疫性血小板减少症(Immune thrombocytopenia, ITP)患者中大部分存在疲劳，经验证的、可靠的疲劳量表已用于ITP评估，这有助于对其发病机制和干预效果进行调查研究。有效的ITP治疗可以改善疲劳，但临床医生在评估ITP疾病负担时应考虑干预疲劳的策略，可借鉴和参考其他慢性病相关性疲劳的治疗方法和策略，ITP相关疲劳也可从中医药治疗中获益。</p></sec><sec id="s2"><title>关键词</title><p>免疫性血小板减少症，疲劳，生活质量</p></sec><sec id="s3"><title>Immune Thrombocytopenia-Related Fatigue</title><p>Xiaoyong Wu<sup>*</sup>, Yunlong Wang</p><p>First Affiliated Hospital, Guizhou University of Traditional Chinese Medicine, Guiyang Guizhou</p><p><img src="//html.hanspub.org/file/46-1571558x5_hanspub.png" /></p><p>Received: Sep. 4<sup>th</sup>, 2020; accepted: Sep. 18<sup>th</sup>, 2020; published: Sep. 25<sup>th</sup>, 2020</p><p><img src="//html.hanspub.org/file/46-1571558x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Fatigue is an important aspect of health-related quality of life (HRQoL). It is also a common manifestation of chronic diseases, which seriously affects the quality of life of patients and can have significant socioeconomic consequences. Most of both adults and children with immune thrombocytopenia (ITP) suffer from fatigue. Validated, reliable fatigue scale has been developed for the use in ITP. These will facilitate future investigation of its pathogenesis and the effectiveness of intervention. Although effective ITP treatment can improve fatigue, clinicians should consider strategies for intervention fatigue when assessing the burden of ITP disease. Clinicians can learn from other chronic disease related fatigue treatment methods and strategies, ITP related fatigue can also benefit from the treatment of Traditional Chinese Medicine.</p><p>Keywords:Immune Thrombocytopenia, Fatigue, Quality of Life</p><disp-formula id="hanspub.37832-formula44"><graphic xlink:href="//html.hanspub.org/file/46-1571558x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/46-1571558x8_hanspub.png" /> <img src="//html.hanspub.org/file/46-1571558x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>免疫性血小板减少症(immune thrombocytopenia, ITP)是一种获得性免疫介导的出血性疾病，主要表现为外周血小板(PLT)计数低于100 &#215; 10<sup>9</sup>/L。ITP患者可能没有症状，也可能出现皮肤黏膜及危及生命的出血 [<xref ref-type="bibr" rid="hanspub.37832-ref1">1</xref>]。国内外研究表明，无论出血问题如何，ITP患者都经常报告疲劳和健康相关的生活质量(HRQoL)下降 [<xref ref-type="bibr" rid="hanspub.37832-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.37832-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.37832-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.37832-ref5">5</xref>]。疲劳已成为影响ITP患者HRQoL的重要因素 [<xref ref-type="bibr" rid="hanspub.37832-ref6">6</xref>]，目前研究认为ITP相关性疲劳与ITP疾病本身和(或)治疗相关，表现为与机体能量消耗不相符、睡眠或休息不能缓解乏力 [<xref ref-type="bibr" rid="hanspub.37832-ref7">7</xref>]。国内外ITP诊疗指南均指出，ITP患者的健康不仅是将PLT计数维持在安全范围，降低出血风险，改善生活质量及疲劳状态同样重要 [<xref ref-type="bibr" rid="hanspub.37832-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.37832-ref8">8</xref>]。本文对ITP相关性疲劳进行阐述，为临床医生在临床实践及研究中关注ITP相关性疲劳提供参考，对于ITP相关性疲劳患者临床获益具有重要意义。</p></sec><sec id="s6"><title>2. ITP疲劳的衡量</title><p>ITP 相关性疲劳的定义尚缺乏统一标准，杨冉 [<xref ref-type="bibr" rid="hanspub.37832-ref7">7</xref>] 等参考癌因性疲乏和慢性疲劳综合征(CFS)定义，将ITP相关性疲劳定义为：一种与ITP和(或) ITP治疗有关的、持续性疲劳及精力不足的主观感觉，通常不能为睡眠或休息所缓解，常伴有身体、情绪、认知、职业方面的功能障碍。在临床研究中，通常使用自我报告疲劳量表或问卷来评价疲劳。目前，针对ITP包含对疲劳进行评估的HRQoL工具有儿童用KIT [<xref ref-type="bibr" rid="hanspub.37832-ref9">9</xref>] 及成人ITP评估问卷(ITP-PAQ) [<xref ref-type="bibr" rid="hanspub.37832-ref10">10</xref>]。儿童用KIT [<xref ref-type="bibr" rid="hanspub.37832-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.37832-ref12">12</xref>]、ITP-PAQ [<xref ref-type="bibr" rid="hanspub.37832-ref13">13</xref>]、FACIT-F及SF-36v2已在ITP临床研究显示出可接受的可靠性和有效性 [<xref ref-type="bibr" rid="hanspub.37832-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.37832-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.37832-ref14">14</xref>]。ITP-PAQ特异性评估ITP健康相关生活质量如症状、疲劳、焦虑、恐惧、社交活动和总体生活质量等多个方面，根据ITP普遍关注的HRQOL方面的问题设计开发而来，最终版本包括11个问题和10个量表。这些评估量表为ITP相关性疲劳提供了研究工具及基础，对门诊或住院患者都较为实用。</p></sec><sec id="s7"><title>3. ITP相关性疲劳现状</title><p>Yang等 [<xref ref-type="bibr" rid="hanspub.37832-ref3">3</xref>] 研究表明中国成人ITP的HRQoL受损，且疲劳负担比健康人群更大，CITP的FACIT-F评分最差。李洋等 [<xref ref-type="bibr" rid="hanspub.37832-ref4">4</xref>] 用FACIT-F对207例ITP患者进行疲劳评分，低于文献报道的健康人群FACIT-F得分。Ni等 [<xref ref-type="bibr" rid="hanspub.37832-ref15">15</xref>] 对1160例成人ITP患者临床特征分析发现疲劳是出血之外的严重症状，196例(16.89%)有疲劳症状，且女性患者更更常见。一项关于986例成人ITP的调查研究报告显示疲劳是ITP最频繁发生和最苦恼的症状之一 [<xref ref-type="bibr" rid="hanspub.37832-ref16">16</xref>]。Newton等 [<xref ref-type="bibr" rid="hanspub.37832-ref17">17</xref>] 采用横断面调查，用FIS评估了585例英国和68例美国ITP，39% (英国)和22% (美国)的患报告有严重的疲劳(FIS ≥ 40)，明显高于正常人群的2.5%。在2项Romiplostim治疗ITP的随机、安慰对照试验中，用ITP-PAQ对HRQoL进行基线评估，在44个评估项目中，疲劳是5个最差的评分之一 [<xref ref-type="bibr" rid="hanspub.37832-ref18">18</xref>]。Mitchell [<xref ref-type="bibr" rid="hanspub.37832-ref19">19</xref>] 等研究提示ITP患者疲劳严重程度在7年内没有改善。Bussel等 [<xref ref-type="bibr" rid="hanspub.37832-ref20">20</xref>] 用李克特量表(Likert scale)对76例ITP进行横断面调查研究提示，58%的ITP报告得分 ≥ 5，表明疲劳干扰了他们的工作，家庭或社交生活。治疗之前，35%的人每天报告疲劳，13%的人每周报告2次疲劳。尽管进行了治疗，但仍有相似的比例报告每天(39%)或每周两次(16%)疲劳。有调查研究表明，在过去1周内，有89% (n = 276)的ITP患者感到疲劳，使用和不使用类固醇治疗的患者报告了相似的疲劳率 [<xref ref-type="bibr" rid="hanspub.37832-ref21">21</xref>]。一项来自13个国家的1507份调查研究显示，在诊断和调查完成时，疲劳是最常见最严重的症状，而患者最想解决的三种症状之一是疲劳 [<xref ref-type="bibr" rid="hanspub.37832-ref22">22</xref>]。Sarpatwari等 [<xref ref-type="bibr" rid="hanspub.37832-ref23">23</xref>] 对成人及儿童ITP健康相关生活方式进行邮件问卷调查，696 (88.1%)名成人及94 (11.9%)名儿童返回了完整的调查(44.7%回应率)，有12.5%的人报告说由于疲劳而“总是”或“经常”不能工作或失学。一项意大利调查研究表明有31%儿童ITP唯一的症状是疲劳 [<xref ref-type="bibr" rid="hanspub.37832-ref24">24</xref>]。最新研究表明，34.3%成人ITP患者在诊断时报告有疲劳 [<xref ref-type="bibr" rid="hanspub.37832-ref25">25</xref>]，54% (29/54)儿童和62% (26/42)青少年有中度至重度疲劳，新诊断和持续ITP平均疲劳评分高于慢性ITP [<xref ref-type="bibr" rid="hanspub.37832-ref5">5</xref>]。以上研究均表明，成人、儿童及青少年ITP患者均承受了相当大的疲劳负担。</p></sec><sec id="s8"><title>4. 影响ITP相关性疲劳的因素</title><p>目前关于ITP相关性疲劳可能与血小板减少、药物治疗、疾病活动等相关 [<xref ref-type="bibr" rid="hanspub.37832-ref26">26</xref>]。以PLT计数来衡量，疲劳与疾病的严重程度是否相关尚不完全清楚。有研究表明疲劳与PLT计数显著相关，PLT计数较低的患者疲劳症状更明显(P &lt; 0.05) [<xref ref-type="bibr" rid="hanspub.37832-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.37832-ref27">27</xref>]，PLT计数是疲劳的独立危险因素 [<xref ref-type="bibr" rid="hanspub.37832-ref17">17</xref>] [<xref ref-type="bibr" rid="hanspub.37832-ref28">28</xref>]，PLT计数低时ITP患者的体能下降，当PLT计数增加时疲劳改善 [<xref ref-type="bibr" rid="hanspub.37832-ref18">18</xref>]。但中国的一项用SF-36评估成人ITP生活质量的横断面研究提示PTL计数(&lt;30, 30~100, &gt;100 &#215; 10<sup>9</sup>/L)不是体能/精力的重要预测指标 [<xref ref-type="bibr" rid="hanspub.37832-ref29">29</xref>]。值得关注的是，PLT过低易引起皮肤黏膜出血、瘀伤，长期慢性出血导致缺铁性贫血常伴有疲劳，可能直接或间接影响情绪和精力。</p><p>情绪及睡眠障碍通常与慢性病疲劳相关，ITP患者因为出血、瘀伤等而存在明显的焦虑、抑郁问题，Terrell等 [<xref ref-type="bibr" rid="hanspub.37832-ref30">30</xref>] 研究表明16%~25% ITP患者至少有中等度的抑郁，需要药物改善睡眠。Newton等 [<xref ref-type="bibr" rid="hanspub.37832-ref17">17</xref>] 认为无出血症状ITP患者疲劳的危险因素是日间困倦。李洋等 [<xref ref-type="bibr" rid="hanspub.37832-ref4">4</xref>] 研究表明影响疲劳的因素包括睡眠质量、焦虑和抑郁情绪。情绪及睡眠障碍可能既是导致ITP患者疲劳的原因，也是结果，从而形成不良循环而影响疲劳的发生发展。</p><p>疲劳是药物的常见副作用，但其引起疲劳的机制尚未完全了解。在使用皮质类固醇(CS)治疗的ITP患者中，与CS相关的33种症状中有25种症状(包括疲劳)发生率高于没有使用CS治疗的患者 [<xref ref-type="bibr" rid="hanspub.37832-ref16">16</xref>]。单因素分析表明疲劳与CS治疗有关 [<xref ref-type="bibr" rid="hanspub.37832-ref17">17</xref>]。在利妥昔单抗VS安慰剂RCT研究中，接受利妥昔单抗治疗的患者有22% (7/32)报告疲劳 [<xref ref-type="bibr" rid="hanspub.37832-ref31">31</xref>]。关于血小板生成素受体激动Romiplostim及Eltrombopag治疗ITP的研究表明，疲劳是治疗过程中最常见的不良反应之一，Romiplostim疲劳发生率为13%~32% [<xref ref-type="bibr" rid="hanspub.37832-ref32">32</xref>] [<xref ref-type="bibr" rid="hanspub.37832-ref33">33</xref>]。Eltrombopag劳发生率为9%~17% [<xref ref-type="bibr" rid="hanspub.37832-ref34">34</xref>]。一项针对91例ITP患者自我报告调查研究显示，接受CS、利妥昔单抗、丙种球蛋白、Romiplostim及Eltrombopag等药物治疗，所有患者报告治疗过程经历了至少一种副作用，疲劳占86% [<xref ref-type="bibr" rid="hanspub.37832-ref35">35</xref>]。治疗ITP的新药Fostamatinib是脾脏酪氨酸激酶(SYK)抑制药，II期临床试验中，治疗相关疲劳发生率43.8% [<xref ref-type="bibr" rid="hanspub.37832-ref36">36</xref>]。这些研究均提示药物治疗可以引起疲劳。</p><p>炎症、免疫激活等被认为慢性病、自身免疫性疾病出现是疲劳的根本原因 [<xref ref-type="bibr" rid="hanspub.37832-ref37">37</xref>] [<xref ref-type="bibr" rid="hanspub.37832-ref38">38</xref>]。基于ITP免疫紊乱的特点，有学者提出“促炎细胞因子网络激活”可能为ITP相关性疲劳的发病机制 [<xref ref-type="bibr" rid="hanspub.37832-ref26">26</xref>]。促炎细胞因子如白介素-1 (IL-1)、IL-6、肿瘤坏死因子-α (TNF-α)、干扰素-α (IFN-α)在自身免疫疾病、慢性病的疲劳中其重要作用 [<xref ref-type="bibr" rid="hanspub.37832-ref37">37</xref>] [<xref ref-type="bibr" rid="hanspub.37832-ref39">39</xref>]。促炎细胞因子引起行为改变包括疲劳，精神运动迟缓，厌食，快感不足，嗜睡，认知功能障碍和情绪低落等 [<xref ref-type="bibr" rid="hanspub.37832-ref40">40</xref>]。研究发现，ITP患者体内炎性细胞因子分泌失衡，致使机体长期处于炎性微环境中，ITP患者血清中促炎因子IL-8、IL-17、IL-22、TNF-α和IFN-γ升高，抑炎因子IL-4、CD40L、TGF-β和IL-10降低 [<xref ref-type="bibr" rid="hanspub.37832-ref41">41</xref>] [<xref ref-type="bibr" rid="hanspub.37832-ref42">42</xref>] [<xref ref-type="bibr" rid="hanspub.37832-ref43">43</xref>]。且IL-1A、IL-6、IL-17F、TNF-α、IFN-γ基因单核苷酸多态性与ITP的发生、发展相关 [<xref ref-type="bibr" rid="hanspub.37832-ref44">44</xref>]。促炎细胞因子在ITP的发病中起重要作用 [<xref ref-type="bibr" rid="hanspub.37832-ref45">45</xref>] [<xref ref-type="bibr" rid="hanspub.37832-ref46">46</xref>]。</p></sec><sec id="s9"><title>5. ITP相关性疲劳的治疗</title><p>目前，还没有针对ITP疲劳的治疗药物，但有效的ITP治疗是改善疲劳的最佳方法。进一步了解其发病机理可能会提出其他干预目标，如潜在的、需要药物治疗病症：睡眠障碍、贫血或铁缺乏症、情绪障碍或社会心理问题、合并症和药物副作用等。ITP相关性疲劳可以借鉴其他疾病引起的疲劳干预措施，如癌性疲乏、慢性疲劳综合征(CFS)等。对于癌性疲乏，多种非药物干预措在不同程度上被证实有效，包括运动、心理社会干预、认知行为疗法(CBT)、瑜伽、针灸等 [<xref ref-type="bibr" rid="hanspub.37832-ref47">47</xref>]。药物如辅酶Q10 [<xref ref-type="bibr" rid="hanspub.37832-ref48">48</xref>]，金刚烷胺、盐酸哌醋甲酯、莫达非尼、Omega-3和Omega-6脂肪酸等，但还需进一步研究 [<xref ref-type="bibr" rid="hanspub.37832-ref49">49</xref>] [<xref ref-type="bibr" rid="hanspub.37832-ref50">50</xref>]；疲劳人群也可从中医药治疗中获益 [<xref ref-type="bibr" rid="hanspub.37832-ref51">51</xref>] [<xref ref-type="bibr" rid="hanspub.37832-ref52">52</xref>]。近年来，中医药在治疗ITP取得显著成效的同时，在改善ITP疲劳症状方面具有显著优势，张玲、王珺等 [<xref ref-type="bibr" rid="hanspub.37832-ref53">53</xref>] [<xref ref-type="bibr" rid="hanspub.37832-ref54">54</xref>] 采用随机对照、多中心临床试验的方法，用健脾益气摄血方治疗脾气虚型ITP，结果提示该方能改善ITP患者体倦乏力、神疲懒言等症状。杨冉等 [<xref ref-type="bibr" rid="hanspub.37832-ref55">55</xref>] 研究提示益气养阴和血方可改善CITP患者HRQoL及减轻疾病相关的疲劳。王明镜等 [<xref ref-type="bibr" rid="hanspub.37832-ref56">56</xref>] 研究表明益气摄血中药可显著改善ITP患者体力评分及FACIT-F评分而缓解疲劳状态。</p></sec><sec id="s10"><title>6. 小结与展望</title><p>疲劳是一种重要的病症，ITP相关性疲劳正越来越多地被国内外学者关注。经过验证的、可重复的、特定疾病的HRQoL和疲劳评估工具的开发研究，为ITP相关性疲劳研究奠定了一定基础。疲劳的原因很多，个体之间及疾病与治疗过程均有所不同，ITP异质性发病机制为更好地了解免疫失衡导致ITP相关疲劳提供了参考，但仍需要进一步深入研究ITP相关疲劳的病因病机。寻找ITP相关性疲劳诊断和疗效评估的靶标，除了PLT计数、免疫功能标志物如T/B淋巴细胞活性、炎性细胞因子外，潜在的研究对象包括线粒体功能、基因易感性、血小板微粒、炎性基因多态性等。临床实践中，有效的ITP治疗可以改善疲劳，但临床医生在评估出血症状、PLT计数的同时，应该评估HRQoL及疲劳，并考虑干预疲劳的策略。ITP相关性疲劳研究应该立足整体，结合传统中医药优势，进行病证结合研究将为ITP相关性疲劳提供理论及临床依据。</p></sec><sec id="s11"><title>基金项目</title><p>国家自然科学基金项目(81260539)；贵州省高校优秀科技创新人才支持计划(黔教合KY字[<xref ref-type="bibr" rid="hanspub.37832-ref2013">2013</xref>]139号)。2015年贵州省千层次创新人才计划。</p></sec><sec id="s12"><title>文章引用</title><p>吴晓勇,王云龙. 免疫性血小板减少症相关性疲劳Immune Thrombocytopenia-Related Fatigue[J]. 临床医学进展, 2020, 10(09): 2162-2168. https://doi.org/10.12677/ACM.2020.109326</p></sec><sec id="s13"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.37832-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Liu, X.G., Bai, X.C., Chen, F.P., et al. (2018) Chinese Guidelines for Treatment of Adult Primary Immune Thrombocytopenia. International Journal of Hematology, 107, 615-623. &lt;br&gt;https://doi.org/10.1007/s12185-018-2445-z</mixed-citation></ref><ref id="hanspub.37832-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Efficace, F., Mandelli, F., Fazi, P., et al. (2016) Health-Related Quality of Life and Burden of Fatigue in Patients with Primary Immune Thrombocytopenia by Phase of Disease. American Journal of Hematology, 91, 995-1001.  
&lt;br&gt;https://doi.org/10.1002/ajh.24463</mixed-citation></ref><ref id="hanspub.37832-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Yang, R., Yao, H., Lin, L., et al. (2019) Health-Related Quality of Life and Burden of Fatigue in Chinese Patients with Immune Thrombocytopenia: A Cross-Sectional Study. Indian Journal of Hematology and Blood Transfusion, 36, 1-8.  
&lt;br&gt;https://doi.org/10.1007/s12288-019-01124-7</mixed-citation></ref><ref id="hanspub.37832-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">李洋, 吕明恩, 郝亚停, 等. 成人原发免疫性血小板减少症患者疲劳症状及影响因素分析[J]. 中华血液学杂志, 2017, 38(5): 384-389.</mixed-citation></ref><ref id="hanspub.37832-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Grace, R.F., Klaassen, R.J., Shimano, K.A., et al. (2020) Fatigue in Children and Adolescents with Immune Thrombocytopenia. British Journal of Haematology. &lt;br&gt;https://doi.org/10.1111/bjh.16751</mixed-citation></ref><ref id="hanspub.37832-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Matzdorff, A., Meyer, O., Ostermann, H., et al. (2018) Immune Thrombocytopenia-Current Diagnostics and Therapy: Recommendations of a Joint Working Group of DGHO, ÖGHO, SGH, GPOH, and DGTI. Oncology Research and Treatment, 41, 1-30. &lt;br&gt;https://doi.org/10.1159/000492187</mixed-citation></ref><ref id="hanspub.37832-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">杨冉, 林琳, 沈群. 原发免疫性血小板减少症相关性疲劳的研究进展[J]. 中国实用内科杂志, 2020, 40(3): 252-255.</mixed-citation></ref><ref id="hanspub.37832-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Neunert, C.E. and Cooper, N. (2018) Evidence-Based Management of Immune Thrombocytopenia: ASH Guideline Update. Hematology, ASH Education Program, 30, 568-575. &lt;br&gt;https://doi.org/10.1182/asheducation-2018.1.568</mixed-citation></ref><ref id="hanspub.37832-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Klaassen, R.J., Blanchette, V.S., Barnard, D., et al. (2007) Validity, Reliability, and Responsiveness of a New Measure of Health-Related Quality of Life in Children with Immune Thrombocytopenic Purpura: The Kids’ ITP Tools. The Journal of Pediatrics, 150, 510-515. &lt;br&gt;https://doi.org/10.1016/j.jpeds.2007.01.037</mixed-citation></ref><ref id="hanspub.37832-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">王网娣. ITP-PAQ特异性评价原发免疫性血小板减少症患者的生活质量[D]: [硕士学位论文]. 济南: 山东大学, 2018.</mixed-citation></ref><ref id="hanspub.37832-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Klaassen, R.J., Blanchette, V., Burke, T.A., et al. (2013) Quality of Life in Childhood Immune Thrombocytopenia: International Validation of the Kids’ ITP Tools. Pediatric Blood &amp; Cancer, 60, 95-100.  
&lt;br&gt;https://doi.org/10.1002/pbc.24257</mixed-citation></ref><ref id="hanspub.37832-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">杨晓东. 原发性免疫性血小板减少症治疗后生存质量调查[J]. 血栓与止血学, 2016, 22(1): 57-60.</mixed-citation></ref><ref id="hanspub.37832-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Trotter, P. and Hill, Q.A. (2018) Immune Thrombocytopenia: Improving Quality of Life and Patient Outcomes. Patient Related Outcome Measures, 9, 369-384. &lt;br&gt;https://doi.org/10.2147/PROM.S140932</mixed-citation></ref><ref id="hanspub.37832-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Signorovitch, J., Brainsky, A. and Grotzinger, K.M. (2011) Validation of the FACIT-Fatigue Subscale, Selected Items from FACT-Thrombocytopenia, and the SF-36v2 in Patients with Chronic Immune Thrombocytopenia. Quality of Life Research, 20, 1737-1744. &lt;br&gt;https://doi.org/10.1007/s11136-011-9912-9</mixed-citation></ref><ref id="hanspub.37832-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Ni, J., Zeng, Q.S., Chen, Y., et al. (2015) Analysis of Epidemiological and Clinic Features of 1160 Adult Patients with Immune Thrombocytopenia. Journal of Medical Imaging and Health Informatics, 5, 800-806.  
&lt;br&gt;https://doi.org/10.1166/jmihi.2015.1460</mixed-citation></ref><ref id="hanspub.37832-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Berti, D., Moons, P., Dobbels, F., et al. (2008) Impact of Corticosteroid-Related Symptoms in Patients with Immune Thrombocytopenic Purpura: Results of a Survey of 985 Patients. Clinical Therapeutics, 30, 1540-1552.  
&lt;br&gt;https://doi.org/10.1016/j.clinthera.2008.08.005</mixed-citation></ref><ref id="hanspub.37832-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Newton, J.L., Reese, J.A., Watson, S.I., et al. (2011) Fatigue in Adult Patients with Primary Immune Thrombocytopenia. European Journal of Haematology, 86, 420-429. &lt;br&gt;https://doi.org/10.1111/j.1600-0609.2011.01587.x</mixed-citation></ref><ref id="hanspub.37832-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">George, J.N., Mathias, S.D., Go, R.S., et al. (2009) Improved Quality of Life for Romiplostim Treated Patients with Chronic Immune Thrombocytopenic Purpura: Results from Two Randomized, Placebo-Controlled Trials. British Journal of Haematology, 144, 409-415. &lt;br&gt;https://doi.org/10.1111/j.1365-2141.2008.07464.x</mixed-citation></ref><ref id="hanspub.37832-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Mitchell, E., Frith, J. and Newton, J. (2019) Fatigue and Cognitive Impairment in Immune Thrombocytopenic Purpura Remain Stable over Time: Short Report from a Longitudinal Study. British Journal of Haematology, 186, 777-781.  
&lt;br&gt;https://doi.org/10.1111/bjh.15993</mixed-citation></ref><ref id="hanspub.37832-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Bussel, J.B., Kruse, A., Kruse, C., et al. (2019) The Burden of Disease and IMPACT of Immune Thrombocytopenia (ITP) on Patients: Results from an ITP Survey. Blood, 134, 1076. &lt;br&gt;https://doi.org/10.1182/blood-2019-131351</mixed-citation></ref><ref id="hanspub.37832-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Kruse, A., Kruse, C., Potthast, N., et al. (2019) Mental Health and Treatment in Patients with Immune Thrombocytopenia (ITP); Data from the Platelet Disorder Support Association (PDSA) Patient Registry. Blood, 134, 2362.  
&lt;br&gt;https://doi.org/10.1182/blood-2019-122278</mixed-citation></ref><ref id="hanspub.37832-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Kruse, C., Kruse, A., Watson, S., et al. (2018) Patients with Immune Thrombocytopenia (ITP) Frequently Experience Severe Fatigue But Is It Under-Recognized by Physicians: Results from the ITP World Impact Survey (I-WISh). Blood, 132, 2273. &lt;br&gt;https://doi.org/10.1182/blood-2018-99-112378</mixed-citation></ref><ref id="hanspub.37832-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Sarpatwari, A., Watson, S., Erqou, S., et al. (2020) Health-Related Lifestyle in Adults and Children with Primary Immune Thrombocytopenia (ITP). British Journal of Haematology, 151, 189-191.  
&lt;br&gt;https://doi.org/10.1111/j.1365-2141.2010.08322.x</mixed-citation></ref><ref id="hanspub.37832-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Giordano, P., Lassandro, G., di Meo, N.A., et al. (2019) A Narrative Approach to Describe QoL in Children with Chronic ITP. Frontiers in Pediatrics, 7, 344. &lt;br&gt;https://doi.org/10.3389/fped.2019.00163</mixed-citation></ref><ref id="hanspub.37832-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Wang, L., Xu, L., Hao, H., et al. (2020) First Line Treatment of Adult Patients with Primary Immune Thrombocytopenia: A Real-World Study. Platelets, 31, 55-61. &lt;br&gt;https://doi.org/10.1080/09537104.2019.1572875</mixed-citation></ref><ref id="hanspub.37832-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Grace, R.F. and Neunert, C. (2016) Second-Line Therapies in Immune Thrombocytopenia. Hematology, ASH Education Program, 2016, 698-706. &lt;br&gt;https://doi.org/10.1182/asheducation-2016.1.698</mixed-citation></ref><ref id="hanspub.37832-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Snyder, C.F., Mathias, S.D., Cella, D., et al. (2008) Health-Related Quality of Life of Immune Thrombocytopenic Purpura Patients: Results from a Web-Based Survey. Current Medical Research and Opinion, 24, 2767-1776.  
&lt;br&gt;https://doi.org/10.1185/03007990802377461</mixed-citation></ref><ref id="hanspub.37832-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">杨冉, 林琳, 季建敏, 等. 中文版慢性病治疗功能评估–疲劳量表在ITP患者中的应用及疲劳影响因素分析[J]. 临床血液学杂志, 2019, 32(3): 213-217.</mixed-citation></ref><ref id="hanspub.37832-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Zhou, Z., Yang, L., Chen, Z., et al. (2007) Health-Related Quality of Life Measured by the Short Form 36 in Immune Thrombocytopenic Purpura: A Cross-Sectional Survey in China. European Journal of Haematology, 78, 518-523.  
&lt;br&gt;https://doi.org/10.1111/j.1600-0609.2007.00844.x</mixed-citation></ref><ref id="hanspub.37832-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Terrell, D.R., Reese, J.A., Branesky, D., et al. (2016) Depression in Adult Patients with Primary Immune Thrombocytopenia. American Journal of Hematology, 91, e462-e463. &lt;br&gt;https://doi.org/10.1002/ajh.24484</mixed-citation></ref><ref id="hanspub.37832-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Arnold, D.M., Heddle, N.M., Carruthers, J., et al. (2012) A Pilot Randomized Trial of Adjuvant Rituximab or Placebo for Nonsplenectomized Patients with Immune Thrombocytopenia. Blood, 119, 1356-1362.  
&lt;br&gt;https://doi.org/10.1182/blood-2011-08-374777</mixed-citation></ref><ref id="hanspub.37832-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Janssens, A., Tarantino, M.D., Bird, R., et al. (2011) Final Results from an International, Multi-Center, Single-Arm Study Evaluating the Safety and Efficacy of Romiplostim in Adults with Primary Immune Thrombocytopenia (ITP). Blood, 118, 3279. &lt;br&gt;https://doi.org/10.1182/blood.V118.21.3279.3279</mixed-citation></ref><ref id="hanspub.37832-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Kuter, D.J., Bussel, J.B., Newland, A., et al. (2013) Long-Term Treatment with Romiplostim in Patients with Chronic Immune Thrombocytopenia: Safety and Efficacy. British Journal of Haematology, 161, 411-423.  
&lt;br&gt;https://doi.org/10.1111/bjh.12260</mixed-citation></ref><ref id="hanspub.37832-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Wong, R.S.M., Saleh, M.N., Khelif, A., et al. (2017) Safety and Efficacy of Long-Term Treatment of Chronic/Persistent ITP with Eltrombopag: Final Results of the EXTEND Study. Blood, 130, 2527-2536.  
&lt;br&gt;https://doi.org/10.1182/blood-2017-04-748707</mixed-citation></ref><ref id="hanspub.37832-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Shaffer, C.S., Haq, N. and Bussel, J.B. (2012) Survey of the Side Effects of ITP Therapies. Blood, 120, 3327.  
&lt;br&gt;https://doi.org/10.1182/blood.V120.21.3327.3327</mixed-citation></ref><ref id="hanspub.37832-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Newland, A., Lee, E.J., McDonald, V., et al. (2018) Fostamatinib for Persistent/Chronic Adult Immune Thrombocytopenia. Immunotherapy, 10, 9-25. &lt;br&gt;https://doi.org/10.2217/imt-2017-0097</mixed-citation></ref><ref id="hanspub.37832-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Norheim, K.B., Jonsson, G. and Omdal, R. (2011) Biological Mechanisms of Chronic Fatigue. Rheumatology (Oxford), 50, 1009-1018. &lt;br&gt;https://doi.org/10.1093/rheumatology/keq454</mixed-citation></ref><ref id="hanspub.37832-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Morris, G., Berk, M., Walder, K., et al. (2015) Central Pathways Causing Fatigue in Neuro-Inflammatory and Autoimmune Illnesses. BMC Medicine, 13, 28. &lt;br&gt;https://doi.org/10.1186/s12916-014-0259-2</mixed-citation></ref><ref id="hanspub.37832-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Morris, G., Berk, M., Galecki, P., et al. (2016) The Neuro-Immune Pathophysiology of Central and Peripheral Fatigue in Systemic Immune-Inflammatory and Neuro-Immune Diseases. Molecular Neurobiology, 53, 1195-1219.  
&lt;br&gt;https://doi.org/10.1007/s12035-015-9090-9</mixed-citation></ref><ref id="hanspub.37832-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Silverman, M.N., Heim, C.M., Nater, U.M., et al. (2010) Neuroendocrine and Immune Contributors to Fatigue. PM R, 2, 338-346. &lt;br&gt;https://doi.org/10.1016/j.pmrj.2010.04.008</mixed-citation></ref><ref id="hanspub.37832-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">王明镜, 许勇钢, 丁晓庆, 等. 免疫性血小板减少症患者促炎因子与抑炎因子分泌失衡[J]. 中国实验血液学杂志, 2018, 26(2): 522-527.</mixed-citation></ref><ref id="hanspub.37832-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">周正菊, 张友山, 梁彩霞, 等. ITP患者外周血Th9、Th17和Treg细胞水平及IL-9、IL-17和TGF-β表达在ITP发病中的作用[J]. 中国实验血液学杂志, 2019, 27(1): 180-184.</mixed-citation></ref><ref id="hanspub.37832-ref43"><label>43</label><mixed-citation publication-type="other" xlink:type="simple">王洪志, 朱世荣, 胡晓梅, 等. 气不摄血证免疫性血小板减少症患者血管活性物质及相关炎症因子变化与临床意义[J]. 世界科学技术-中医药现代化, 2020, 22(3): 901-906.</mixed-citation></ref><ref id="hanspub.37832-ref44"><label>44</label><mixed-citation publication-type="other" xlink:type="simple">Audia, S., Mahevas, M., Samson, M., et al. (2017) Pathogenesis of Immune Thrombocytopenia. Autoimmunity Reviews, 16, 620-632. &lt;br&gt;https://doi.org/10.1016/j.autrev.2017.04.012</mixed-citation></ref><ref id="hanspub.37832-ref45"><label>45</label><mixed-citation publication-type="other" xlink:type="simple">McKenzie, C.G., Guo, L., Freedman, J., et al. (2013) Cellular Immune Dysfunction in Immune Thrombocytopenia (ITP). British Journal of Haematology, 163, 10-23. &lt;br&gt;https://doi.org/10.1111/bjh.12480</mixed-citation></ref><ref id="hanspub.37832-ref46"><label>46</label><mixed-citation publication-type="other" xlink:type="simple">Li, H.Y., Zhang, D.L., Zhang, X., et al. (2015) Interleukin-7 Is Decreased and Maybe Plays a Pro-Inflammatory Function in Primary Immune Thrombocytopenia. Platelets, 26, 243-249. &lt;br&gt;https://doi.org/10.3109/09537104.2014.903392</mixed-citation></ref><ref id="hanspub.37832-ref47"><label>47</label><mixed-citation publication-type="other" xlink:type="simple">Thong, M.S.Y., van Noorden, C.J.F., Steindorf, K., et al. (2020) Cancer-Related Fatigue: Causes and Current Treatment Options. Current Treatment Options in Oncology, 21, 17. &lt;br&gt;https://doi.org/10.1007/s11864-020-0707-5</mixed-citation></ref><ref id="hanspub.37832-ref48"><label>48</label><mixed-citation publication-type="other" xlink:type="simple">Mehrabani, S., Askari, G., Miraghajani, M., et al. (2019) Effect of Coenzyme Q10 Supplementation on Fatigue: A Systematic Review of Interventional Studies. Complementary Therapies in Medicine, 43, 181-187.  
&lt;br&gt;https://doi.org/10.1016/j.ctim.2019.01.022</mixed-citation></ref><ref id="hanspub.37832-ref49"><label>49</label><mixed-citation publication-type="other" xlink:type="simple">Peppone, L.J., Inglis, J.E., Mustian, K.M., et al. (2019) Multicenter Randomized Controlled Trial of Omega-3 Fatty Acids versus Omega-6 Fatty Acids for the Control of Cancer-Related Fatigue among Breast Cancer Survivors. JNCI Cancer Spectrum, 3, pkz005. &lt;br&gt;https://doi.org/10.1093/jncics/pkz005</mixed-citation></ref><ref id="hanspub.37832-ref50"><label>50</label><mixed-citation publication-type="other" xlink:type="simple">Mücke, M., Mochamat, Cuhls, H., et al. (2016) Pharmacological Treatments for Fatigue Associated with Palliative Care: Executive Summary of a Cochrane Collaboration Systematic Review. Journal of Cachexia, Sarcopenia and Muscle, 7, 23-27. &lt;br&gt;https://doi.org/10.1002/jcsm.12101</mixed-citation></ref><ref id="hanspub.37832-ref51"><label>51</label><mixed-citation publication-type="other" xlink:type="simple">Zhou, S.S. and Jiang, J.G. (2019) Anti-Fatigue Effects of Active Ingredients from Traditional Chinese Medicine: A Review. Current Medicinal Chemistry, 26, 1833-1848. &lt;br&gt;https://doi.org/10.2174/0929867324666170414164607</mixed-citation></ref><ref id="hanspub.37832-ref52"><label>52</label><mixed-citation publication-type="other" xlink:type="simple">赖秋媛, 谢辑文, 陈道睿, 等. 中医药治疗运动性疲劳研究[J]. 新中医, 2018, 50(9): 28-33.</mixed-citation></ref><ref id="hanspub.37832-ref53"><label>53</label><mixed-citation publication-type="other" xlink:type="simple">张玲, 陈科, 张雅月, 等. 健脾益气摄血方治疗免疫性血小板减少症临床疗效及其机制研究[J]. 北京中医药大学学报, 2020, 43(4): 343-352.</mixed-citation></ref><ref id="hanspub.37832-ref54"><label>54</label><mixed-citation publication-type="other" xlink:type="simple">王珺, 张蕴, 张玲, 等. 健脾益气摄血颗粒治疗免疫性血小板减少症临床疗效观察[J]. 中华中医药杂志, 2018, 33(12): 5700-5704.</mixed-citation></ref><ref id="hanspub.37832-ref55"><label>55</label><mixed-citation publication-type="other" xlink:type="simple">杨冉, 姚浩, 季建敏, 等. 益气养阴和血方治疗慢性原发免疫性血小板减少症的临床观察[J]. 中国中西医结合杂志, 2019, 39(3): 305-309.</mixed-citation></ref><ref id="hanspub.37832-ref56"><label>56</label><mixed-citation publication-type="other" xlink:type="simple">王明镜, 全日城, 丁晓庆, 等. 益气摄血方治疗气不摄血证免疫性血小板减少症多中心、随机、双盲、对照研究[J]. 中国中西医结合杂志, 2020, 40(8): 929-934.</mixed-citation></ref></ref-list></back></article>